Cargando…

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing-Yue, Wang, Quan-Wei, Yang, Xin-Yu, Yang, Wei, Li, Dong-Rui, Jin, Jing-Yu, Zhang, Hui-Cong, Zhang, Xian-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945324/
https://www.ncbi.nlm.nih.gov/pubmed/36843578
http://dx.doi.org/10.3389/fendo.2023.1085799
_version_ 1784892117863104512
author Wang, Jing-Yue
Wang, Quan-Wei
Yang, Xin-Yu
Yang, Wei
Li, Dong-Rui
Jin, Jing-Yu
Zhang, Hui-Cong
Zhang, Xian-Feng
author_facet Wang, Jing-Yue
Wang, Quan-Wei
Yang, Xin-Yu
Yang, Wei
Li, Dong-Rui
Jin, Jing-Yu
Zhang, Hui-Cong
Zhang, Xian-Feng
author_sort Wang, Jing-Yue
collection PubMed
description Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists.
format Online
Article
Text
id pubmed-9945324
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99453242023-02-23 GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach Wang, Jing-Yue Wang, Quan-Wei Yang, Xin-Yu Yang, Wei Li, Dong-Rui Jin, Jing-Yu Zhang, Hui-Cong Zhang, Xian-Feng Front Endocrinol (Lausanne) Endocrinology Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists. Frontiers Media S.A. 2023-02-01 /pmc/articles/PMC9945324/ /pubmed/36843578 http://dx.doi.org/10.3389/fendo.2023.1085799 Text en Copyright © 2023 Wang, Wang, Yang, Yang, Li, Jin, Zhang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wang, Jing-Yue
Wang, Quan-Wei
Yang, Xin-Yu
Yang, Wei
Li, Dong-Rui
Jin, Jing-Yu
Zhang, Hui-Cong
Zhang, Xian-Feng
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
title GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
title_full GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
title_fullStr GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
title_full_unstemmed GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
title_short GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
title_sort glp−1 receptor agonists for the treatment of obesity: role as a promising approach
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945324/
https://www.ncbi.nlm.nih.gov/pubmed/36843578
http://dx.doi.org/10.3389/fendo.2023.1085799
work_keys_str_mv AT wangjingyue glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach
AT wangquanwei glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach
AT yangxinyu glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach
AT yangwei glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach
AT lidongrui glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach
AT jinjingyu glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach
AT zhanghuicong glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach
AT zhangxianfeng glp1receptoragonistsforthetreatmentofobesityroleasapromisingapproach